European Journal of Medicinal Chemistry p. 1028 - 1038 (2018)
Update date:2022-08-11
Topics:
Solomon, V. Raja
Pundir, Sheetal
Le, Hoang-Thanh
Lee, Hoyun
In an attempt to develop effective and safe anticancer agents, we designed, synthesized and examined 23 novel quinacrine (QC) derivatives by combining the 9-aminoacridine scaffold and the [1,3]thiazinan-4-ones group. Most of these hybrids showed strong anticancer activities, among which 3-(3-(6-chloro-2-methoxyacridin-9-ylamino)propyl)-2-(thiophen-2-yl)-1,3-thiazinan-4-one (25; VR151) effectively killed many different cancer cell types, including eight breast cancer cell lines with different genetic background, two prostate cancer and two lung cancer cell lines. In contrast, compound 25 is less effective against non-cancer cells, suggesting it may be less toxic to humans. Our data showed that cancer cells are arrested in S phase for a prolonged period due to the down-regulation of DNA replication, leading to eventual cell death. We have also shown that the S phase arrest may be resulted by the down-regulation of cyclin A coupled with the continued up-regulation of cyclin E, which coincide with the down-regulation of mTor-S6K and mTor-4EBP1 pathways.
View MoreContact:021-61840961 021-61840962
Address:No.157,Zhuguang Rd, Qingpu, Shanghai, China
Xinxiang Junlong Biological Technology Co., Ltd.
website:https://junlongbio.lookchem.com/
Contact:86-13525059581
Address:Xinxiang City, Henan Province
website:http://www.joyochem.com
Contact:0531-82687558, 0531-82687326
Address:Factory Building 11, Jinan Comprehensive free trade zone, Shandong, China
XI'AN CHUKANG BIOTECHNOLOGY CO.,LTD
Contact:29-63685658 63685359
Address:Room 3-1202,Building 1,Oriental oasis,East of Xianning Road,Xi'an,Shaanxi 710043 P.R.China
Xi'an Costrong Pharmaceutical Co., Ltd.
Contact:029- 68576496
Address:Room 2004,Shuibao Building,No.190,South Erhuan Rd, Yanta District,Xi'an,Shaan Xi,China
Doi:10.1248/cpb.47.1157
(1999)Doi:10.1111/j.1540-8191.2001.tb00527.x
()Doi:10.1002/omr.1270210608
(1983)Doi:10.1007/BF01167753
()Doi:10.1021/jm400026k
(2013)Doi:10.1021/ic901722g
(2009)